Olanzapine/samidorphan

< Olanzapine
Olanzapine/samidorphan
Combination of
OlanzapineAtypical antipsychotic
SamidorphanOpioid antagonist
Clinical data
Trade namesLybalvi
Other namesALKS-3831; OLZ/SAM
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa621051
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist. Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect. The formulation was approved for medical use in the United States in May 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.